Normalization of hemoglobin level in patients with chronic kidney disease and anemia

New England Journal of Medicine

Volumn 355, Issue 20, 2006, Pages 2071-2084

  Drüeke, Tilman B ^a,i   Locatelli, Francesco ^b   Clyne, Naomi ^c   Eckardt, Kai Uwe ^d,e   Macdougall, Iain C ^f   Tsakiris, Dimitrios ^g   Burger, Hans Ulrich ^h   Scherhag, Armin ^h  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b A MANZONI HOSPITAL   (Italy)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

^g GENERAL HOSPITAL OF VERIA   (Greece)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; ERYTHROPOIETIN; HEMOGLOBIN; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ADULT; ANEMIA; ANGINA PECTORIS; ARTICLE; BRONCHITIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DIARRHEA; DISEASE COURSE; DIZZINESS; FEMALE; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HEADACHE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; INFECTION; INFLUENZA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROLOGIC DISEASE; PERIPHERAL VASCULAR DISEASE; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VASCULAR DISEASE; VOMITING;

ANEMIA; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; QUALITY OF LIFE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL ANALYSIS;

EID: 33751002326     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa062276     Document Type: Article

References (38)

1. Weiner DE, Tighiouart H, Vlagopoulos PT, et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 2005;16:1803-10.
2. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-9.
3. Madore F, Lowrie EG, Brugnara C, et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol 1997;8:1921-9.
4. Möcks J. Cardiovascular mortality in haemodialysis patients treated with epoetin beta - a retrospective study. Nephron 2000;86:455-62.
5. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003;63:1908-14.
6. Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant 2003;18:Suppl 2:ii2-ii6.
7. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19:Suppl 2:ii1-ii47.
8. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:94-111.
9. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90.
10. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000;58:1325-35.
11. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005;16:2180-9.
12. Portolés J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997;29:541-8.
13. Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000;35:250-6.
14. Valderrábano F. Improvement and prevention of left ventricular hypertrophy in predialysis patients. J Am Soc Nephrol 2000;11:78A. abstract.
15. Roger SD, McMahon LP, Clarkson A, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004;15:148-56.
16. Levin A, Djurdjev O, Thompson C, et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005;46:799-811.
17. Macdougall IC. CREATE: new strategies for early anaemia management in renal insufficiency. Nephrol Dial Transplant 2003;18:Suppl 2:ii13-ii16.
18. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
19. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989;2:358-67.
20. Kisslo J. Recommendations for continuous quality improvement in echocardiography. J Am Soc Echocardiogr 1995;8:S1-S28.
21. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-34.
22. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61.
23. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181-91.
24. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
25. Cusick M, Chew EY, Hoogwerf B, et al. Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study report no. 26. Kidney Int 2004;66:1173-9.
26. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004;66:1131-8.
27. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int 2004;66:1596-605.
28. Rossert J, Levin A, Roger SD, et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 2006;47:738-29.
29. Roth D, Smith RD, Schulman G, et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994;24:777-84.
30. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003;18:353-61.
31. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004;66:753-60.
32. Sharples EJ, Patel N, Brown P, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004;15:2115-24.
33. Rossert J, Eckardt KU. Erythropoietin receptors: their role beyond erythropoiesis. Nephrol Dial Transplant 2005;20:1025-8.
34. Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995;25:548-54.
35. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000;15:1425-30.
36. Klang B, Clyne N. Well-being and functional ability in uraemic patients before and after having started dialysis treatment. Scand J Caring Sci 1997;11:159-66.
37. Clyne N, Jogestrand T, Lins LE, Pehrsson SK. Progressive decline in renal function induces a gradual decrease in total hemoglobin and exercise capacity. Nephron 1994;67:322-6.
38. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47:Suppl 3:S11-S145. [Erratum, Am J Kidney Dis 2006;48:518.]